Scarica l'app Stockscreener
9.05
2.27%
-0.21
Precedente Chiudi:
$9.26
Aprire:
$9.3
Volume 24 ore:
663.05K
Relative Volume:
0.51
Capitalizzazione di mercato:
$732.15M
Reddito:
$204.89M
Utile/perdita netta:
$-157.30M
Rapporto P/E:
-4.2869
EPS:
-2.1111
Flusso di cassa netto:
$-97.76M
1 W Prestazione:
+1.23%
1M Prestazione:
+0.78%
6M Prestazione:
-18.10%
1 anno Prestazione:
-23.82%
Intervallo 1D:
$8.984
$9.3113
Intervallo di 1 settimana:
$8.7816
$9.7296
Portata 52W:
$8.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Nome
Phathom Pharmaceuticals Inc
Settore
Industria
Telefono
(877) 742-8466
Indirizzo
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
9.05 | 695.75M | 204.89M | -157.30M | -97.76M | -2.1111 |
VRTX
Vertex Pharmaceuticals Inc
|
557.96 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
843.47 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,053.46 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
148.87 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.87 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-12-12 | Iniziato | Raymond James | Strong Buy |
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Iniziato | Stifel | Buy |
| 2024-01-05 | Reiterato | Needham | Buy |
| 2023-08-09 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-05-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2021-02-17 | Iniziato | BMO Capital Markets | Outperform |
| 2021-02-02 | Iniziato | Guggenheim | Buy |
| 2020-06-26 | Downgrade | Goldman | Neutral → Sell |
| 2019-11-20 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Goldman | Neutral |
| 2019-11-19 | Iniziato | Jefferies | Buy |
| 2019-11-19 | Iniziato | Needham | Buy |
Mostra tutto
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.2%What's Next? - MarketBeat
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff? - Stocktwits
3,496,808 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by Carlyle Group Inc. - MarketBeat
PHAT Maintains Overweight Rating -- Price Target Lowered to $14 - GuruFocus
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Phathom Pharmaceuticals (PHAT) Advances 4.36% to $9.58, Approaches Key Resistance at $10.06MESA MA - vinanet.vn
Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts - Yahoo Finance
Phathom Pharmaceuticals, Inc. (PHAT) Investigation: Bronstein, Ge - The National Law Review
Phathom Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | PHAT | US71722W1071 - marketscreener.com
PHAT Holds Near $9.18 as Phathom Pharmaceuticals Consolidates Within Key Trading RangeStop Hunt - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Connect - ACCESS Newswire
Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (PHAT) Short Interest & Short Float | Updated Aug 2026 $PHAT - MarketBeat
Phathom Pharmaceuticals, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuti - The National Law Review
Renaissance Technologies LLC Acquires New Holdings in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals, Inc. (PHAT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
GYRE Stock Price and Chart — NASDAQ:GYRE - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Investors to Reach Out - ACCESS Newswire
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 5.5%Here's Why - MarketBeat
Levi & Korsinsky Notifies Investors of Pending - GlobeNewswire
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT) - Business Wire
Weekly Recap: Q2 revenue surge and Investigation into NASDAQ:PHAT guidance claim - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Stockholders to Reach Out - ACCESS Newswire
925,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Perceptive Advisors LLC - MarketBeat
Phathom Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PHAT) 2026-08-01 - Seeking Alpha
PHAT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $26 - GuruFocus
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals - Morningstar
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $20 - Moomoo
Raymond James Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $21 - Moomoo
H.C. Wainwright reiterates Phathom stock rating on strong revenue growth By Investing.com - Investing.com Canada
Phathom Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Phathom Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Guggenheim cuts Phathom Pharmaceuticals price target on guidance reduction By Investing.com - Investing.com Canada
Earnings call transcript: Phathom posts Q2 2026 revenue beat, shares fall premarket - Investing.com Canada
Phathom Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Phathom Q2 Revenue Jumps 88% to $74.3 Million - Quiver Quantitative
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - globenewswire.com
Phathom Pharmaceuticals Q2 Results: Sales surge 88% YoY - scanx.trade
BlackRock (PHAT) discloses 4.38M-share passive stake in Pharmaceuticals Inc - stocktitan.net
625,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by EcoR1 Capital LLC - MarketBeat
PHAT|Phathom Pharmaceuticals Inc|Price:11.950|Chg%:+0.510 - TradingKey
Phathom Pharmaceuticals Inc - TradingKey
Phathom Pharmaceuticals Inc (PHAT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SummitTX Capital L.P. Purchases 478,065 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals Inc (PHAT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Phathom Pharmaceuticals Inc (PHAT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Phathom Pharmaceuticals Inc Azioni (PHAT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Phathom Pharmaceuticals Inc Azioni (PHAT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Jan 13 '26 |
Option Exercise |
10.30 |
8,750 |
90,125 |
131,000 |
| Parikh Asit | Director |
Dec 19 '25 |
Option Exercise |
10.30 |
8,750 |
90,125 |
122,250 |
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
0.64%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):